C2N 8E12

Drug Profile

C2N 8E12

Alternative Names: ABBV-8E12; C2N-8E12

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator C2N Diagnostics
  • Developer AbbVie; C2N Diagnostics
  • Class Antibodies; Antiparkinsonians; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 20 Jul 2017 Adverse event data from a phase I trial in Progressive supranuclear palsy presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 19 Dec 2016 Adverse events data from a phase I clinical trial in Progressive supranuclear palsy (In elderly, In adults) released by C2N Diagnostics (NCT02494024)
  • 09 Dec 2016 AbbVie and C2N Diagnostics plans a phase II trial for Alzheimer’s disease and Progressive supranuclear palsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top